Unicycive therapeutics.

Unicycive Therapeutics, Inc. 4300 El Camino Real Suite 210 Los Altos, CA 94022 United States 650 351 4495 https://unicycive.com Sector(s) : Healthcare Industry : Biotechnology Full Time Employees : 12

Unicycive therapeutics. Things To Know About Unicycive therapeutics.

JuSun. Shares of kidney disease company, Unicycive Therapeutics (NASDAQ:UNCY) jump 114% premarket after the Company signed a securities purchase agreement with certain institutional investors that ...Contact - Unicycive. 4300 El Camino Real, Suite #210. Los Altos, CA 94022. +1 (650) 351-4495. Name. First Last. Contact Unicycive Therapeutics (UNCY) to learn more about our developing treatments for medical conditions. Provide the latest market data of Unicycive Therapeutics (UNCY), including prices, candlestick charts of various timeframes, basic information and real-time ...7 Nov 2022 ... Unicycive Therapeutics, Inc. is a biotechnology company dedicated to developing treatments for certain medical conditions. The Company is ...Unicycive Therapeutics reports Q3 2023 GAAP EPS of -$0.13 and reveals cash and cash equivalents of $14.3 million, projected to last until H2 2024.

ENDOGENA THERAPEUTICS. is a clinical-stage biotech company that discovers and develops first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs. Our approach has the potential of a paradigm shift to treat degenerative conditions related to aging and genetic disorders.

TTOO. T2 Biosystems, Inc. Common Stock. $0.56 +0.1067 +23.54%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market ...

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel investigational phosphate-binding agent being ...Laumas has served as a member of the board of directors of Bioxcel Therapeutics Inc. since 2017 and a board member of Unicycive Therapeutics Inc. since 2018. He previously served as a board member of 9 Meters Biopharma, Inc. from 2020-21, its Executive Chairman from 2014-20, including its Chief Executive Officer from 2019-20.Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ...Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational ...

In today’s fast-paced world, finding activities that provide relaxation and a sense of accomplishment is more important than ever. One such activity that has gained popularity in recent years is crafting and building.

Unicycive Therapeutics Rebounds and Closes Up 17%. By Luisa Beltran. Updated July 13, 2021, 6:24 pm EDT / Original July 13, 2021, 10:36 am EDT. Share. Resize. Reprints.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing …Oct 23, 2023 · About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is ... In today’s fast-paced world, finding activities that provide relaxation and a sense of accomplishment is more important than ever. One such activity that has gained popularity in recent years is crafting and building.Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ...

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with ...2022年7月18日,生物技术公司Uncycive Therapeutics与李氏大药厂签订协议,授予后者于中国大陆、香港及若干其他亚洲市场开发、营销和商业化Renazorb(二氧碳酸镧)的独家权利。根据协议,Unicycive公司将于协议签订时收取100万美元的预付账款,并于产品在中国推出时收取最多100万美元的里程碑款项。John Townsend. John Townsend is Chief Financial Officer at Unicycive Therapeutics Inc. Previously, he has served as Vice President of Finance and Chief Accounting Officer in a consulting role for Unicycive. He has over 25 years of public and private company experience in industries including biotechnology, medical devices, and high-tech ... Separately, HC Wainwright cut their target price on shares of Unicycive Therapeutics from $7.00 to $4.50 and set a “buy” rating for the company in a research note on Wednesday, August 16th.Legal Name Unicycive Therapeutics, Inc. Stock Symbol NASDAQ:UNCY. Company Type For Profit. Phone Number (650) 384-0642. Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the ...

30 Oct 2023 ... 4 likes, 0 comments - b2i_digital on October 30, 2023: "Unicycive Therapeutics (Nasdaq: $UNCY), a B2i Digital Featured Company, ...Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel investigational phosphate-binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.

Nov 14, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. LOS ALTOS, Calif., Dec. 14, 2020 /PRNewswire/ -- Unicycive Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced it has ...Mar 8, 2023 · Unicycive Therapeutics shareholders should be happy with the total gain of 99% over the last twelve months. And the share price momentum remains respectable, with a gain of 214% in the last three ... Unicycive Therapeutics Report this profile About A physician by training and background - found my passion in bringing new technologies to… Experience Unicycive Therapeutics ...Shalabh Gupta, MD, founded Unicycive and has served as Chief Executive Officer, President, and director since August 2016. Previously, Dr. Gupta served in various other roles, including founder and Chief Executive Officer of Biocycive Inc.; a commercial strategist at Genentech, Inc.; equity researcher covering US pharmaceutical companies at UBS ...Unicycive Therapeutics Stock Performance. Shares of Unicycive Therapeutics stock opened at $0.52 on Monday. Unicycive Therapeutics has a 52-week low of $0.40 and a 52-week high of $2.87. The stock has a market capitalization of $18.07 million, a price-to-earnings ratio of -0.30 and a beta of 2.64.Unicycive Therapeutics (NASDAQ:UNCY) has filed to raise $25 million in an IPO of its common stock, according to an S-1 registration statement. The firm is developing treatments for various kidney ...Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ...US90466Y1038. Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August …

Shalabh Gupta founded Unicycive Therapeutics, Inc., Biocycive, Inc. and Globavir Biosciences, Inc. He is Chairman, President & Chief Executive Officer at Unicycive Therapeutics, Inc. and Chief Executive Officer for Globavir Biosciences, Inc.

Legal Name Unicycive Therapeutics, Inc. Stock Symbol NASDAQ:UNCY. Company Type For Profit. Phone Number (650) 384-0642. Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the ...

The Unicycive Therapeutics interview that had been scheduled to air was recorded prior to the company's recent interactions with the U.S. Food and Drug Administration (FDA or Agency) concerning ...Dr. Shalabh Gupta, MD, founder, chairman of the board of directors and CEO of Unicycive Therapeutics Inc. Shalabh Gupta, MD, founded Unicycive and has served as Chief Executive Officer, President, and director since August 2016. Previously, Dr. Gupta served in various other roles, including founder and Chief Executive Officer of Biocycive Inc.; a commercial strategist […]Jun 29, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, lanthanum dioxycarbonate (LDC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Glancy Prongay & Murray LLP Announces Investigation of Unicycive Therapeutics, Inc. April 14, 2022 06:56 PM Eastern Daylight Time. NEW YORK-- ...Unicycive Therapeutics shareholders should be happy with the total gain of 99% over the last twelve months. And the share price momentum remains respectable, with a gain of 214% in the last three ...6 Jul 2023 ... Unicycive Therapeutics Inc. (NASDAQ: UNCY). Latest News. About US. Overview · Team · The RedChip Way · Why CEO's Hire RedChip ...Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients’ lives. Learn More. The Latest From Vera Patient Stories. Liz Describes …Unicycive Therapeutics (NASDAQ: UNCY) is a prototypical high-upside pharmaceutical stock in many senses. It hasn’t yet commercialized any drugs and it didn’t report any revenues in Q2 of this ...Unicycive Therapeutics, Inc. is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead product candidate, Renazorb, is a novel phosphate binding agent being ...LOS ALTOS, Calif., Oct. 26, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the appointment of Douglas Jermasek as Executive Vice President, Corporate Strategy.LOS ALTOS, Calif., Dec. 14, 2020 /PRNewswire/ -- Unicycive Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced it has ...Oct 23, 2023 · About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is ...

About Unicycive . Unicycive Therapeutics, Inc. is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead product candidate, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development ...Unicycive Therapeutics, Inc.'s latest quarterly earnings per share is $-0.13 with a past EPS surprise of $0.00. The latest EPS estimate is $-0.18. Read more ...Mar 6, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel investigational phosphate-binding agent being ... Instagram:https://instagram. best day trading apps for beginnershealth insurance providers in arizonaoanda vs forexcepton's Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’s.HotSpot Therapeutics, Inc. One Design Center Place Suite 19-600 Boston, MA 02210 +1 (617) 758-8998 [email protected] Science; Smart Allostery™ ... asian stock markets nowwhat is a shadow bank 30 Oct 2023 ... 4 likes, 0 comments - b2i_digital on October 30, 2023: "Unicycive Therapeutics (Nasdaq: $UNCY), a B2i Digital Featured Company, ... best funded trading accounts Unicycive draws Buy rating at Roth on prospects for lead asset Apr. 06, 2023 10:53 AM ET Unicycive Therapeutics, Inc. (UNCY) By: Dulan Lokuwithana , SA News Editor 1 Comment tarabirdInvestors - Unicycive. [WE DO NOT CONTROL THIS SECTION OF THE SITE. WE WILL CONNECT WITH THE THIRD PARTY BUT MAY NEED TO CREATE THE HEADER IMAGE. THIS COULD BE A MAGNIFYING GLASS MADE OUT OF DOTS.] [WE DO NOT CONTROL THIS SECTION OF THE SITE.